Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73


The Roles of Peroxiredoxin and Thioredoxin in Hydrogen Peroxide Sensing and in Signal Transduction.

Netto LE, Antunes F.

Mol Cells. 2016 Jan;39(1):65-71. doi: 10.14348/molcells.2016.2349. Epub 2016 Jan 25. Review.


Peroxiredoxins in Regulation of MAPK Signalling Pathways; Sensors and Barriers to Signal Transduction.

Latimer HR, Veal EA.

Mol Cells. 2016 Jan;39(1):40-5. doi: 10.14348/molcells.2016.2327. Epub 2016 Jan 25. Review.


An unexplored role for Peroxiredoxin in exercise-induced redox signalling?

Wadley AJ, Aldred S, Coles SJ.

Redox Biol. 2016 Aug;8:51-8. doi: 10.1016/j.redox.2015.10.003. Epub 2015 Dec 25. Review.


PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug.

He T, Hatem E, Vernis L, Lei M, Huang ME.

J Exp Clin Cancer Res. 2015 Dec 21;34:152. doi: 10.1186/s13046-015-0270-2.


Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma.

Trzeciecka A, Klossowski S, Bajor M, Zagozdzon R, Gaj P, Muchowicz A, Malinowska A, Czerwoniec A, Barankiewicz J, Domagala A, Chlebowska J, Prochorec-Sobieszek M, Winiarska M, Ostaszewski R, Gwizdalska I, Golab J, Nowis D, Firczuk M.

Oncotarget. 2016 Jan 12;7(2):1717-31. doi: 10.18632/oncotarget.6435.


Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer.

Sun YL, Cai JQ, Liu F, Bi XY, Zhou LP, Zhao XH.

World J Gastroenterol. 2015 Oct 14;21(38):10840-52. doi: 10.3748/wjg.v21.i38.10840.


AIF inhibits tumor metastasis by protecting PTEN from oxidation.

Shen SM, Guo M, Xiong Z, Yu Y, Zhao XY, Zhang FF, Chen GQ.

EMBO Rep. 2015 Nov;16(11):1563-80. doi: 10.15252/embr.201540536. Epub 2015 Sep 28.


Focus on PTEN Regulation.

Bermúdez Brito M, Goulielmaki E, Papakonstanti EA.

Front Oncol. 2015 Jul 27;5:166. doi: 10.3389/fonc.2015.00166. eCollection 2015. Review.


The sulfiredoxin-peroxiredoxin (Srx-Prx) axis in cell signal transduction and cancer development.

Mishra M, Jiang H, Wu L, Chawsheen HA, Wei Q.

Cancer Lett. 2015 Oct 1;366(2):150-9. doi: 10.1016/j.canlet.2015.07.002. Epub 2015 Jul 10. Review.


Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells.

Siernicka M, Winiarska M, Bajor M, Firczuk M, Muchowicz A, Bobrowicz M, Fauriat C, Golab J, Olive D, Zagozdzon R.

Immunology. 2015 Sep;146(1):173-83. doi: 10.1111/imm.12494. Epub 2015 Jul 8.


Glutaminolysis and autophagy in cancer.

Villar VH, Merhi F, Djavaheri-Mergny M, Durán RV.

Autophagy. 2015;11(8):1198-208. doi: 10.1080/15548627.2015.1053680. Review.


Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S.

Semin Cancer Biol. 2015 Dec;35 Suppl:S25-54. doi: 10.1016/j.semcancer.2015.02.006. Epub 2015 Apr 17. Review.


A peroxiredoxin, PRDX-2, is required for insulin secretion and insulin/IIS-dependent regulation of stress resistance and longevity.

Oláhová M, Veal EA.

Aging Cell. 2015 Aug;14(4):558-68. doi: 10.1111/acel.12321. Epub 2015 Mar 23.


Peroxiredoxin 1 promotes pancreatic cancer cell invasion by modulating p38 MAPK activity.

Taniuchi K, Furihata M, Hanazaki K, Iwasaki S, Tanaka K, Shimizu T, Saito M, Saibara T.

Pancreas. 2015 Mar;44(2):331-40. doi: 10.1097/MPA.0000000000000270.


Tuning of peroxiredoxin catalysis for various physiological roles.

Perkins A, Poole LB, Karplus PA.

Biochemistry. 2014 Dec 16;53(49):7693-705. doi: 10.1021/bi5013222. Epub 2014 Dec 1. Review.


Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors.

Xu W, Yang Z, Zhou SF, Lu N.

Drug Des Devel Ther. 2014 Oct 6;8:1745-51. doi: 10.2147/DDDT.S71061. eCollection 2014. Review.


Adenanthin targets peroxiredoxin I/II to kill hepatocellular carcinoma cells.

Hou JK, Huang Y, He W, Yan ZW, Fan L, Liu MH, Xiao WL, Sun HD, Chen GQ.

Cell Death Dis. 2014 Sep 4;5:e1400. doi: 10.1038/cddis.2014.345.


MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.

Patel A, Burton DG, Halvorsen K, Balkan W, Reiner T, Perez-Stable C, Cohen A, Munoz A, Giribaldi MG, Singh S, Robbins DJ, Nguyen DM, Rai P.

Oncogene. 2015 May 14;34(20):2586-96. doi: 10.1038/onc.2014.195. Epub 2014 Jul 14.


Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer.

O'Leary PC, Terrile M, Bajor M, Gaj P, Hennessy BT, Mills GB, Zagozdzon A, O'Connor DP, Brennan DJ, Connor K, Li J, Gonzalez-Angulo AM, Sun HD, Pu JX, Pontén F, Uhlén M, Jirström K, Nowis DA, Crown JP, Zagozdzon R, Gallagher WM.

Breast Cancer Res. 2014 Jul 10;16(4):R79. doi: 10.1186/bcr3691.


Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells.

Sangar V, Funk CC, Kusebauch U, Campbell DS, Moritz RL, Price ND.

Mol Cell Proteomics. 2014 Oct;13(10):2618-31. doi: 10.1074/mcp.M114.040428. Epub 2014 Jul 5.

Items per page

Supplemental Content

Write to the Help Desk